The Cambridge Molecular Diagnostics Laboratory (CMDL) has been established for the development of new technologies in relation to ctDNA analysis using next generation sequencing and for sequencing modified bases in DNA. The lab will work closely with the molecular and digital pathology groups. New sequencing technologies will be capable to being rapidly moved to support their use in clinical trial settings.
The recently established Cancer Molecular Diagnostic Laboratory (CMDL) funded by the NIHR BRC and the Cambridge Cancer Centre (CCC) has the capacity to provide detailed molecular genetic profiling of tumors working under Good Clinical and Laboratory Practice (GCLP) and ISO 15189:2012 guidelines.
CMDL experimental workflows include processing and analysing fresh frozen and formalin-fixed paraffin embedded tissue (FFPE) as well as ctDNA; these workflows are easily translated into standardised protocols for routine analysis.
As part of the Integrative Cancer Program, CMDL is developing protocols for small (targeted re-sequencing of a reduce amplicons number) to medium scale projects (analysis of hundreds of genes in one sequencing experiment) that will enable CCC scientists and clinicians to molecularly characterise cancer patients.